Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysisWon‐Mook Choi, Young‐Suk Lim, Yi‐Hsiang Huang et al.|Journal of Hepatology|2022Cited by 62
Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patientsWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Hepatology|2024Cited by 33
Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort StudyWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Clinical Gastroenterology and Hepatology|2024Cited by 16
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott Fung, Marı́a Buti, Calvin Q. Pan et al.|Alimentary Pharmacology & Therapeutics|2023Cited by 14
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B PatientsJinlin Hou, Jidong Jia, Qin Ning et al.|Journal of Clinical and Translational Hepatology|2024Cited by 7